Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

[News]

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

More... (http://www.news-medical.net/news/20110127/Plexxikon-begins-PLX5622-Phase-1-trial-in-patients-with-rheumatoid-arthritis.aspx)